Visit the conference website  Schedule a meeting with us

Evidera and CorEvitas are excited to join together at ISPOR 2024 this year in booth #619. Please stop by our booth or set up a time to meet with one of our experts about how we can help you identify, generate, and communicate the right evidence to move your products forward towards success.

  • Real-world data and evidence that promotes drug development, regulatory approval and market growth, including proprietary registry, EHR and provider/physician insights
  • Patient-centered research to ensure the patients’ perspectives, outcomes, and preferences are included throughout product development
  • Evidence synthesis and modeling to build your foundation of evidence, simulate expected outcomes, and quantify and demonstrate value
  • Value and access solutions to navigate complex global payer and HTA requirements and changing regulations and communicate that value story effectively
  • Non-interventional studies to generate real-world evidence to inform clinical trial design and meet regulatory and payer post-approval safety and long-term follow-up requirements

Please join us at our following presentations during ISPOR 2024.


Monday, May 6

HEOR Theater Presentation 12:15pm-12:45pm

Advancing the Use of Registry Data to Improve Health Technology Assessment and Payer Evidence

Speakers:

  • Nahila Justo, Executive Director, RWE Integrated Solutions, Evidera, part of PPD clinical research business of Thermo Fisher Scientific
  • Heather Von Allmen, Senior Director, Data Licensing and Partnerships, CorEvitas, part of PPD clinical research business of Thermo Fisher Scientific
  • Almudena Olid Gonzalez, Director, Value and Access Consulting, Evidera, part of PPD clinical research business of Thermo Fisher Scientific
ISPOR FORUM 3:15PM–4:15PM

ISPOR Good Practice Task Force Recommendations on Valuing HRQoL of Children & Adolescents in Economic Evaluation (Pediatric Utilities)

Devlin N, Univ. of Melbourne; Chandler F, Sanofi and Patient Advisory Board Lead, Duchenne UK; Law E, Pfizer; Matza L, Evidera, part of PPD

ISSUE PANEL ─ 1:45PM-2:45PM

In or Out? Challenges in Determining Sample Selection Criteria and Recruitment Approaches for Patient Preference Studies

Janssen EM, Janssen R&D; Gebben DJ, Center for Devices and Radiological Health, U.S. FDA; Whitty J, Evidera, part of PPD; Gonzalez JM, Preference Eval. Research Group, Duke Univ.

POSTER SESSON 1 ─ 10:30AM-1:30PM

EE56: Bearing the brunt: Disproportionate burden among female parent-caregivers in rare disease O’Ruanaidh K, Sandman K

HPR6: Inflation Reduction Act – How will the first 10 drugs selected for Medicare Price Negotiations Impact US Commercial Payers? Sidhu C, Connelly B, Waththuhewa M, Sullivan N

MT3: US Payer Management of Digital Health Technologies:  Recent Updates and a Glimpse into the Future Sidhu C, Waththuhewa M, Sullivan N

PCR39: Exploring Patient and Caregiver Perspectives on Burden Associated with Friedreich ataxia in the USA Lawson R, Setyawan J, Natarajan S, Martin ML, Correll J, Clark A, Bushnell DM, Khan S

POSTER SESSON 2 ─ 3:30PM-6:30PM

MSR22: Automating Systematic Literature Review (SLR) Updates: A Comparative Validation Study of Artificial Intelligence (AI) Versus Human Screeners Cichewicz A, Pande A, Borkowska K, Mittal L, Wittkopf P, Slim M

CO75: Clinical Outcomes Associated With Anti-CD38 Retreatment in Relapsed/Refractory Multiple Myeloma: A Review of the Literature McNamara S, Chorazy J, Pandey A, Bitetti J, Boytsov N, Purser M, Iheanacho I

PCR90: Patient Voice and Patient Engagement in Value Assessment Frameworks and HTA Decision-Making for Gene Therapies Dabbous M, Raza J, Connelly B, Olid Gonzalez A, Sullivan N

PCR56: Are Limitations in Physical Function Relevant and Important Concepts to Assess in Patients on Antithrombotic Therapy for Cardiovascular Conditions? Wyrwich KW, Clark A, Fastenau J, O’Brien E, Kang A, Gaitonde P, Chan EKH, Becker B, Martin M



 

TUESDAY, MAY 7

ISPOR FORUM ─ 11:45AM-12:45PM

ISPOR Good Practice Task Force Recommendations on Valuing HRQoL of Children & Adolescents in Economic Evaluation (Pediatric Utilities)

Devlin N, Univ. of Melbourne; Chandler F, Sanofi and Patient Advisory Board Lead, Duchenne UK; Law E, Pfizer; Matza L, Evidera, part of PPD

PODIUM PRESENTATION ─ 10:15AM-11:15AM

P28: Impact of FDA Expedited Review Programs on New Drug Approval Time Ronnebaum S, Smith D, Andrawes M

POSTER SESSON 3 ─ 10:30AM-1:30PM

EPH104: Public Health Impact of Pediatric BNT162B2 XBB1.5-Adapted COVID-19 Vaccine in the United States Yehoshua A, Yarnoff B, Di Fusco M, Lopez S, Rudolph A, Thoburn E, Marczell K

HTA35: Selection of Appropriate Endpoints for the EU JCA & National Assessments in Select Member States and England for ATMPs Olid Gonzalez A, Laughlin W, Bretton D, D’Ausilio A, Sullivan N

PCR113: Patients’ Perspectives on Bleeding, Bruising, and Other Key Changes Associated With Antithrombotic Treatment Wyrwich KW, Clark A, Fastenau J, O’Brien E, Kang A, Gaitonde P, Chan EKH, Becker B, Martin M

POSTER SESSON 4 ─ 3:30PM-6:30PM

EE309: Cost-Effectiveness Analysis of Velmanase Alfa in Patients with Alpha Mannosidosis from a UK Health Service Perspective Stevenson A, Chang-Douglass S, Kazmierska P, Benedict Á, Azimpour K, Donà F, Dorling P

EE338: NICE Reconsideration for Oncology Drugs Based on Single-Arm Trials Referred to Cancer Drug Fund Wu S, Zou D, Zhang E

PC208: The Association of Intentional Weight Reduction with Symptom Burden and PRO Measures in Patients with Obstructive Sleep Apnea: A Systematic Literature Review Shinde S, Rolland C, Pandey A, Frampton J, Luijken J, Kreuger KA

WD143: Update of our Review of Real-world Evidence in HTA Decision-Making of Gene Therapies in the US, Canada, UK, EU4 and Japan Dabbous M, Waththuhewa M, Olid Gonzalez A, Raza J, Dabbous F, Sullivan N



 

WEDNESDAY, MAY 8

POSTER SESSON 5 ─ 9:00AM-11:00AM

A Non-Representative Sample: Racial and Ethnic Diversity in Clinical Trials of FDA-Approved Drugs Andrawes M, Schaible K, Ronnebaum S